Endometriosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by 
All the vital news, analysis, and commentary curated by our industry experts.
Endometriosis Pipeline Drugs Market Report Overview
Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Endometriosis – Drugs In Development, 2022, provides an overview of the Endometriosis (Women’s Health) pipeline landscape.
Endometriosis is an often painful disorder in which tissue that normally lines the inside of uterus (endometrium) grows outside uterus (endometrial implant). Symptoms include pelvic pain, menstrual cramps, inflammation, infertility and abnormal bleeding. Risk factors age, uterine abnormalities, history of pelvic infection and family history. Treatment includes NSAIDs, birth control pills and progestins.
Report Highlights
Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Endometriosis – Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Endometriosis (Women’s Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Endometriosis (Women’s Health) pipeline guide also reviews of key players involved in therapeutic development for Endometriosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 6, 13, 8, 19, 3 and 3 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 2 and 2 molecules, respectively.
Endometriosis (Women’s Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
– The pipeline guide provides a snapshot of the global therapeutic landscape of Endometriosis (Women’s Health).
– The pipeline guide reviews pipeline therapeutics for Endometriosis (Women’s Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Endometriosis (Women’s Health) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Endometriosis (Women’s Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Endometriosis (Women’s Health)
Reasons to Buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Endometriosis (Women’s Health).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Endometriosis (Women’s Health) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Aptorum Group Ltd
Bayer AG
BCI Pharma SA
Bol Pharma
Chugai Pharmaceutical Co Ltd
Context Therapeutics Inc
Daewoong Pharmaceutical Co Ltd
Egret Therapeutics Inc
Eikonoklastes Therapeutics Inc
ElexoPharm GmbH
Endomet Biosciences Inc
Enteris BioPharma Inc
Eurofarma Laboratorios SA
Evestra Inc
Evotec SE
Ferring International Center SA
Forendo Pharma Ltd
GeneScience Pharmaceuticals Co Ltd
Hangzhou Metai Pharmaceutical Technology Co Ltd
Hope Medicine Inc
Immunitor Inc
Insud Pharma
Ironwood Pharmaceuticals Inc
Jiangsu Hengrui Medicine Co Ltd
Kissei Pharmaceutical Co Ltd
Livzon Pharmaceutical Group Co Ltd
Medibiofarma SL
Mithra Pharmaceuticals SA
Mitsubishi Tanabe Pharma Corp
Myovant Sciences Ltd
Navad Life Sciences Pte Ltd
Nippon Shinyaku Co Ltd
Predictive Therapeutics LLC
PregLem SA
SYNG Pharmaceuticals Inc
Synokem Pharmaceuticals Ltd
Takeda Pharmaceutical Co Ltd
Temple Therapeutics BV
TiumBio Co Ltd
ValiRx Plc
Viramal Ltd
Xbrane Biopharma AB
Table of Contents
Table
Figures
Frequently asked questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Related reports
View more Women's Health reports